Two Sigma Investments LP Reduces Stock Position in Centessa Pharmaceuticals plc (NASDAQ:CNTA)

Two Sigma Investments LP cut its holdings in Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 63.5% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 37,900 shares of the company's stock after selling 66,008 shares during the quarter. Two Sigma Investments LP's holdings in Centessa Pharmaceuticals were worth $635,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Stempoint Capital LP increased its stake in Centessa Pharmaceuticals by 667.3% during the fourth quarter. Stempoint Capital LP now owns 641,964 shares of the company's stock worth $10,753,000 after acquiring an additional 558,302 shares during the last quarter. Shay Capital LLC bought a new position in shares of Centessa Pharmaceuticals during the 4th quarter valued at approximately $239,000. Point72 Asset Management L.P. raised its holdings in Centessa Pharmaceuticals by 26.2% during the 4th quarter. Point72 Asset Management L.P. now owns 3,426,599 shares of the company's stock valued at $57,396,000 after buying an additional 710,936 shares during the period. OMERS ADMINISTRATION Corp bought a new stake in Centessa Pharmaceuticals in the fourth quarter worth $171,000. Finally, Millennium Management LLC boosted its stake in Centessa Pharmaceuticals by 73.0% during the fourth quarter. Millennium Management LLC now owns 398,451 shares of the company's stock worth $6,674,000 after buying an additional 168,072 shares during the period. Institutional investors own 82.01% of the company's stock.

Centessa Pharmaceuticals Trading Down 3.6%

CNTA traded down $0.45 during trading on Thursday, hitting $12.04. 517,622 shares of the stock were exchanged, compared to its average volume of 696,750. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52. The firm has a 50 day simple moving average of $12.53 and a 200 day simple moving average of $15.10. The firm has a market cap of $1.61 billion, a price-to-earnings ratio of -7.87 and a beta of 1.48. Centessa Pharmaceuticals plc has a 1 year low of $8.46 and a 1 year high of $19.09.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.20) earnings per share for the quarter, topping analysts' consensus estimates of ($0.35) by $0.15. As a group, equities analysts expect that Centessa Pharmaceuticals plc will post -1.6 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. Chardan Capital began coverage on shares of Centessa Pharmaceuticals in a research note on Thursday, May 8th. They issued a "buy" rating and a $30.00 target price on the stock. Piper Sandler began coverage on shares of Centessa Pharmaceuticals in a research report on Monday, March 31st. They issued an "overweight" rating and a $38.00 price objective on the stock. Oppenheimer began coverage on shares of Centessa Pharmaceuticals in a research note on Thursday, May 8th. They issued an "outperform" rating and a $6.00 price objective for the company. Guggenheim reaffirmed a "buy" rating and set a $28.00 target price on shares of Centessa Pharmaceuticals in a research note on Wednesday, March 26th. Finally, Needham & Company LLC assumed coverage on Centessa Pharmaceuticals in a report on Wednesday, May 28th. They issued a "buy" rating and a $35.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $27.89.

Insider Activity at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, CEO Saurabh Saha sold 55,000 shares of the business's stock in a transaction dated Thursday, March 20th. The shares were sold at an average price of $16.69, for a total value of $917,950.00. Following the completion of the transaction, the chief executive officer now directly owns 276,017 shares in the company, valued at approximately $4,606,723.73. The trade was a 16.62% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, General Counsel Iqbal J. Hussain sold 6,000 shares of the business's stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $16.45, for a total transaction of $98,700.00. Following the transaction, the general counsel now owns 105,386 shares of the company's stock, valued at approximately $1,733,599.70. This trade represents a 5.39% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 175,398 shares of company stock valued at $2,551,442 over the last ninety days. 7.09% of the stock is owned by company insiders.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.